{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:19:49Z","timestamp":1773278389958,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T00:00:00Z","timestamp":1331769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10620-012-2118-3","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T09:28:10Z","timestamp":1331717290000},"page":"1773-1781","source":"Crossref","is-referenced-by-count":48,"title":["Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies"],"prefix":"10.1007","volume":"57","author":[{"given":"William","family":"Nseir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julnar","family":"Mograbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,15]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","volume":"123","author":"E Bugianesi","year":"2002","unstructured":"Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134\u2013140.","journal-title":"Gastroenterology"},{"key":"2118_CR2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434\u2013438.","journal-title":"Mayo Clin Proc"},{"key":"2118_CR3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver diseases. N Eng J Med. 2002;346:1221\u20131231.","journal-title":"N Eng J Med"},{"key":"2118_CR4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","volume":"37","author":"G Marchesini","year":"2003","unstructured":"Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917\u2013923.","journal-title":"Hepatology"},{"key":"2118_CR5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.mol.0000174153.53683.f2","volume":"16","author":"G Marchesini","year":"2005","unstructured":"Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and metabolic syndrome. Curr Opin Lipidol. 2005;16:421\u2013427.","journal-title":"Curr Opin Lipidol"},{"key":"2118_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0026-0495(93)90210-F","volume":"42","author":"JG Kral","year":"1993","unstructured":"Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548\u2013551.","journal-title":"Metabolism"},{"key":"2118_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1042\/0264-6021:3500389","volume":"350","author":"D Azzout-Marniche","year":"2000","unstructured":"Azzout-Marniche D, B\u00e9card D, Guichard C, Foretz M, Ferr\u00e9 P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J. 2000;350:389\u2013393.","journal-title":"Biochem J"},{"key":"2118_CR8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day CP, James OF. Steatohepatitis: a tale of two \u201chits.\u201d Gastroenterology. 1998;114:842\u2013845.","journal-title":"Gastroenterology"},{"key":"2118_CR9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1053\/jhep.2002.32527","volume":"35","author":"M Charlton","year":"2002","unstructured":"Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898\u2013904.","journal-title":"Hepatology"},{"key":"2118_CR10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1023\/A:1005661516165","volume":"45","author":"N Assy","year":"2000","unstructured":"Assy N, Kaita K, Mymin D, Levy C, Roser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929\u20131934.","journal-title":"Dig Dis Sci"},{"key":"2118_CR11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","volume":"2","author":"C Solderberg","year":"2010","unstructured":"Solderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;2:595\u2013602.","journal-title":"Hepatology"},{"key":"2118_CR12","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s10620-011-1767-y","volume":"56","author":"W Nseir","year":"2011","unstructured":"Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439\u20133449.","journal-title":"Dig Dis Sci"},{"key":"2118_CR13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.89.3.1333","volume":"89","author":"National Cholesterol Education Program","year":"1994","unstructured":"National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 1994;89:1333\u20131445.","journal-title":"Circulation"},{"key":"2118_CR14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11936-009-0028-2","volume":"11","author":"S Tandra","year":"2009","unstructured":"Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272\u2013273.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2118_CR15","doi-asserted-by":"crossref","unstructured":"Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618\u2013624.","DOI":"10.1016\/j.amjmed.2005.02.008"},{"key":"2118_CR16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","volume":"49","author":"M Adiels","year":"2006","unstructured":"Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755\u2013765.","journal-title":"Diabetologia"},{"key":"2118_CR17","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3748\/wjg.v16.i21.2579","volume":"16","author":"W Nseir","year":"2010","unstructured":"Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:2579\u20132588.","journal-title":"World J Gastroenterol"},{"key":"2118_CR18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","volume":"51","author":"A Abid","year":"2009","unstructured":"Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51:918\u2013924.","journal-title":"J Hepatol"},{"key":"2118_CR19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MCO.0b013e328312c353","volume":"11","author":"IA Leclercq","year":"2008","unstructured":"Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care. 2008;11:766\u2013773.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2118_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/er.21.6.697","volume":"21","author":"BL Wajchenberg","year":"2000","unstructured":"Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697\u2013738.","journal-title":"Endocr Rev"},{"key":"2118_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/204748730000700505","volume":"7","author":"HN Ginsberg","year":"2000","unstructured":"Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325\u2013331.","journal-title":"J Cardiovasc Risk"},{"key":"2118_CR22","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","volume":"91","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753\u20134761.","journal-title":"J Clin Endocrinol Metab"},{"key":"2118_CR23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2337\/diabetes.33.4.333","volume":"33","author":"T Mazzone","year":"1984","unstructured":"Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes. 1984;33:333\u2013338.","journal-title":"Diabetes"},{"key":"2118_CR24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"key":"2118_CR25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0165-6147(02)02077-1","volume":"23","author":"G Weitz-Schmidt","year":"2002","unstructured":"Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmol Sci. 2002;23:482\u2013486.","journal-title":"Trends Pharmol Sci"},{"key":"2118_CR26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1523-5378.2010.00803.x","volume":"15","author":"W Nseir","year":"2010","unstructured":"Nseir W, Khateeb J, Tatour I, Haiek S, Samara M, Assy N. Long-term statin therapy affects the severity of chronic gastritis. Helicobacter. 2010;15:510\u2013515.","journal-title":"Helicobacter"},{"key":"2118_CR27","doi-asserted-by":"crossref","unstructured":"Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. 2012;40:41\u201348.","DOI":"10.1007\/s15010-011-0190-9"},{"key":"2118_CR28","doi-asserted-by":"crossref","first-page":"II42","DOI":"10.1161\/01.CIR.0000129500.29229.92","volume":"109","author":"JP Halcox","year":"2004","unstructured":"Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004;109:II42\u2013II48.","journal-title":"Circulation"},{"key":"2118_CR29","first-page":"MS6","volume":"15","author":"T Abel","year":"2009","unstructured":"Abel T, Feher J, Dinya H, Eldin MG, Kovacs A. Safety and efficacy of combined ezetemibe\/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009;15:MS6\u2013MS11.","journal-title":"Med Sci Monit"},{"key":"2118_CR30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","volume":"43","author":"A Nelson","year":"2009","unstructured":"Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990\u2013994.","journal-title":"J Clin Gastroenterol"},{"key":"2118_CR31","first-page":"1117","volume":"56","author":"RG Mihaila","year":"2009","unstructured":"Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology. 2009;56:1117\u20131121.","journal-title":"Hepatogastroenterology"},{"key":"2118_CR32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","volume":"174","author":"LS Rallidis","year":"2004","unstructured":"Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174:193\u2013196.","journal-title":"Atherosclerosis"},{"key":"2118_CR33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"JH Lewis","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453\u20131463.","journal-title":"Hepatology"},{"key":"2118_CR34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","volume":"41","author":"H Hyogo","year":"2011","unstructured":"Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41:1057\u20131065.","journal-title":"Hepatol Res"},{"key":"2118_CR35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","volume":"23","author":"E Gomez-Dominguez","year":"2006","unstructured":"Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garc\u00eda-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemidia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23:1643\u20131647.","journal-title":"Aliment Pharmacol Ther"},{"key":"2118_CR36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver test in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post hoc analysis. Lancet. 2010;376:1916\u20131922.","journal-title":"Lancet"},{"key":"2118_CR37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1155\/2003\/857869","volume":"17","author":"M Kiyici","year":"2003","unstructured":"Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713\u2013718.","journal-title":"Can J Gastroenterol"},{"key":"2118_CR38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","volume":"22","author":"VG Athyros","year":"2006","unstructured":"Athyros VG, Mikhaildis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Cur Med Res Opin. 2006;22:873\u2013883.","journal-title":"Cur Med Res Opin"},{"key":"2118_CR39","first-page":"39","volume":"16","author":"EF Georgescu","year":"2007","unstructured":"Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of preliminary study. J Gastrointestin Liver Dis. 2007;16:39\u201346.","journal-title":"J Gastrointestin Liver Dis"},{"key":"2118_CR40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","volume":"45","author":"Y Kimura","year":"2010","unstructured":"Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750\u2013757.","journal-title":"J Gastroenterol"},{"key":"2118_CR41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajg.2011.04.008","volume":"12","author":"W Samy","year":"2011","unstructured":"Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011;12:80\u201385.","journal-title":"Arab J Gastroenterol"},{"key":"2118_CR42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2005.08.021","volume":"184","author":"S Antonopoulos","year":"2006","unstructured":"Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006;184:233\u2013234.","journal-title":"Atherosclerosis"},{"key":"2118_CR43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-2275(20)39388-3","volume":"13","author":"SM Grundy","year":"1972","unstructured":"Grundy SM, Ahrens EH Jr, Salen G, Schreibman PH, Nestel PJ. Mechanisms of action of clofibrate on cholesterol metabolism patients with hyperlipidemia. J Lipid Res. 1972;13:531\u2013551.","journal-title":"J Lipid Res"},{"key":"2118_CR44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","volume":"23","author":"J Laurin","year":"1996","unstructured":"Laurin J, Lindor KD, Crippin JS, et al. Urseodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464\u20131467.","journal-title":"Hepatology"},{"key":"2118_CR45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","volume":"31","author":"M Basaranoglu","year":"1999","unstructured":"Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384.","journal-title":"J Hepatol"},{"key":"2118_CR46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","volume":"40","author":"C Fernandez-Miranda","year":"2008","unstructured":"Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic liver disease. Dig Liver Dis. 2008;40:200\u2013205.","journal-title":"Dig Liver Dis"},{"key":"2118_CR47","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","volume":"65","author":"PL McCormack","year":"2005","unstructured":"McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidemia. Drugs. 2005;65:2719\u20132740.","journal-title":"Drugs"},{"key":"2118_CR48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccl.2008.06.007","volume":"26","author":"JF Paolini","year":"2008","unstructured":"Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin\/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008;26:547\u2013560.","journal-title":"Cardiol Clin"},{"key":"2118_CR49","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","volume":"95","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with non-alcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:2727\u20132735.","journal-title":"J Clin Endocrinol Metab"},{"key":"2118_CR50","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0149-2918(03)80281-3","volume":"25","author":"L Jeu","year":"2003","unstructured":"Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe, a cholesterol-absorption inhibitor. Clin Ther. 2003;25:2352\u20132387.","journal-title":"Clin Ther"},{"key":"2118_CR51","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altamann","year":"2004","unstructured":"Altamann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201\u20131204.","journal-title":"Science"},{"key":"2118_CR52","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","volume":"102","author":"M Garcia-Calvo","year":"2005","unstructured":"Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102:8132\u20138137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2118_CR53","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","volume":"40","author":"MH Davidson","year":"2002","unstructured":"Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125\u20132134.","journal-title":"J Am Coll Cardiol"},{"key":"2118_CR54","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1872-034X.2010.00638.x","volume":"40","author":"M Yoneda","year":"2010","unstructured":"Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment on non-alcoholic steatohepatitis: an open label, pilot study. Hepatol Res. 2010;40:613\u2013621.","journal-title":"Hepatol Res"},{"key":"2118_CR55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2337\/dc10-0393","volume":"33","author":"DC Chan","year":"2010","unstructured":"Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010;33:1143\u20131149.","journal-title":"Diabetes Care"},{"key":"2118_CR56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","volume":"46","author":"H Park","year":"2011","unstructured":"Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101\u2013107.","journal-title":"J Gastroenterol"},{"key":"2118_CR57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1126\/science.3303333","volume":"237","author":"LH Storlien","year":"1987","unstructured":"Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science. 1987;237:885\u2013888.","journal-title":"Science"},{"key":"2118_CR58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/CS20030326","volume":"106","author":"J Araya","year":"2004","unstructured":"Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6\/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004;106:635\u2013643.","journal-title":"Clin Sci"},{"key":"2118_CR59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1566524033479537","volume":"3","author":"S Yu","year":"2003","unstructured":"Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561\u2013572.","journal-title":"Curr Mol Med"},{"key":"2118_CR60","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00125-005-0053-y","volume":"49","author":"P Flachs","year":"2006","unstructured":"Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetelogia. 2006;49:394\u2013397.","journal-title":"Diabetelogia"},{"key":"2118_CR61","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-2036.2006.02885.x","volume":"23","author":"M Cappani","year":"2006","unstructured":"Cappani M, Callela F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic staetosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol. 2006;23:1143\u20131151.","journal-title":"Aliment Pharmacol"},{"key":"2118_CR62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.dld.2007.10.003","volume":"40","author":"L Spadaro","year":"2008","unstructured":"Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver diseases. Dig Liver Dis. 2008;40:194\u2013199.","journal-title":"Dig Liver Dis"},{"key":"2118_CR63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","volume":"47","author":"S Zelber-Sagi","year":"2007","unstructured":"Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47:711\u2013717.","journal-title":"J Hepatol"},{"key":"2118_CR64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MCG.0b013e31815591aa","volume":"42","author":"N Tanaka","year":"2008","unstructured":"Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413\u2013418.","journal-title":"J Clin Gastroenterol"},{"key":"2118_CR65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/09637486.2010.487480","volume":"61","author":"F Sofi","year":"2010","unstructured":"Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid\u2013enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. In J Food Sci Nutr. 2010;61:792\u2013802.","journal-title":"In J Food Sci Nutr"},{"key":"2118_CR66","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.3748\/wjg.14.6395","volume":"14","author":"FS Zhu","year":"2008","unstructured":"Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty liver acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14:6395\u20136400.","journal-title":"World J Gastroenterol"},{"key":"2118_CR67","first-page":"927","volume":"50","author":"D Weismantel","year":"2001","unstructured":"Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol lowering agents? J Fam Pract. 2001;50:927\u2013928.","journal-title":"J Fam Pract"},{"key":"2118_CR68","doi-asserted-by":"crossref","unstructured":"American Gastroenterology Association medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002;123:1702\u20131704.","DOI":"10.1053\/gast.2002.36569"},{"key":"2118_CR69","first-page":"1702","volume":"123","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;123:1702\u20131704.","journal-title":"Circulation"},{"key":"2118_CR70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0939-4753(04)80008-5","volume":"14","author":"G Anfossi","year":"2004","unstructured":"Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis. 2004;14:215\u2013224.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2118_CR71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","volume":"11","author":"SS Bhardawaj","year":"2007","unstructured":"Bhardawaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11:597\u2013613.","journal-title":"Clin Liver Dis"},{"key":"2118_CR72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2011.06.013","volume":"5","author":"M Tzefos","year":"2011","unstructured":"Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipdol. 2011;5:450\u2013459.","journal-title":"J Clin Lipdol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2118-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2118-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:36:03Z","timestamp":1742700963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2118-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,15]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2118-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,15]]}}}